8 results
Keyword Efluelda Remove keyword
-
List item
Opinion/decision on a Paediatric investigation plan (PIP): Split influenza virus, inactivated containing antigens equivalent to the A/H1N1-like strain, Split influenza virus, inactivated containing antigens equivalent to the A/H3N2-like strain, Split influenza virus, inactivated containing antigens equivalent to the B-like strain (Victoria lineage), Split influenza virus, inactivated containing antigens equivalent to the B-like strain (Yamagata lineage)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Vaccines
PIP number: EMEA-002359-PIP01-18-M04, Route(s) of administration: Intramuscular use, Pharmaceutical form(s): Solution for injection
Decision date: 10/02/2022, Last updated: 17/04/2023, Compliance check: XKey facts Efluelda Split influenza virus, inactivated … strain (Yamagata lineage) (Efluelda and associated names), (EMEA- 002359-PIP01-18-M04 … strain (Yamagata lineage) (Efluelda and associated names), (EMEA- 002359-PIP01-18-M04 … -
List item
List of medicines under additional monitoring (updated)
Last updated: 30/05/2023 -
List item
Public data from Article 57 database
Last updated: 17/10/2022 -
List item
Annual reports and work programmes (updated)
Last updated: 15/05/2023 -
List item
News: EMA annual report 2022 published (new)
Last updated: 15/05/2023 -
List item
News: Annual report 2020 published
Last updated: 14/06/2021 -
List item
News: EMA publishes annual report 2021
Last updated: 10/06/2022 -
List item
Pharmacovigilance: Regulatory and procedural guidance
Last updated: 29/04/2016